JP7387885B2 - 癌処置のための多重特異性結合タンパク質 - Google Patents

癌処置のための多重特異性結合タンパク質 Download PDF

Info

Publication number
JP7387885B2
JP7387885B2 JP2022520371A JP2022520371A JP7387885B2 JP 7387885 B2 JP7387885 B2 JP 7387885B2 JP 2022520371 A JP2022520371 A JP 2022520371A JP 2022520371 A JP2022520371 A JP 2022520371A JP 7387885 B2 JP7387885 B2 JP 7387885B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022520371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551081A5 (enExample
JP2022551081A (ja
Inventor
ヒップ，スザンヌ
アダム，パウル
ジェゲルウスキ，ミヒャエル
ガネサン，ラクマー
ゴーマン，フィリップ・ニコラス
グプタ，パンカジ
グプタ，プリヤンカー
ラサロ，マルシオ
シェアー，ジャスティン・エム
ヴォイノフ，ウラジミール・エイチ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68136317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7387885(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2022551081A publication Critical patent/JP2022551081A/ja
Publication of JP2022551081A5 publication Critical patent/JP2022551081A5/ja
Priority to JP2023194494A priority Critical patent/JP7809680B2/ja
Application granted granted Critical
Publication of JP7387885B2 publication Critical patent/JP7387885B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022520371A 2019-10-02 2020-10-01 癌処置のための多重特異性結合タンパク質 Active JP7387885B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023194494A JP7809680B2 (ja) 2019-10-02 2023-11-15 癌処置のための多重特異性結合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19201200.3 2019-10-02
EP19201200 2019-10-02
PCT/EP2020/077586 WO2021064137A2 (en) 2019-10-02 2020-10-01 Multi-specific binding proteins for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023194494A Division JP7809680B2 (ja) 2019-10-02 2023-11-15 癌処置のための多重特異性結合タンパク質

Publications (3)

Publication Number Publication Date
JP2022551081A JP2022551081A (ja) 2022-12-07
JP2022551081A5 JP2022551081A5 (enExample) 2022-12-27
JP7387885B2 true JP7387885B2 (ja) 2023-11-28

Family

ID=68136317

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520371A Active JP7387885B2 (ja) 2019-10-02 2020-10-01 癌処置のための多重特異性結合タンパク質
JP2023194494A Active JP7809680B2 (ja) 2019-10-02 2023-11-15 癌処置のための多重特異性結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023194494A Active JP7809680B2 (ja) 2019-10-02 2023-11-15 癌処置のための多重特異性結合タンパク質

Country Status (24)

Country Link
US (2) US11732045B2 (enExample)
EP (1) EP4038100A2 (enExample)
JP (2) JP7387885B2 (enExample)
KR (1) KR20220075383A (enExample)
CN (4) CN122103354A (enExample)
AR (1) AR120138A1 (enExample)
AU (1) AU2020358893A1 (enExample)
BR (1) BR112022004047A2 (enExample)
CA (1) CA3153372A1 (enExample)
CL (1) CL2022000664A1 (enExample)
CO (1) CO2022003552A2 (enExample)
CR (1) CR20220136A (enExample)
DO (1) DOP2022000060A (enExample)
EC (1) ECSP22019193A (enExample)
IL (1) IL291817A (enExample)
JO (1) JOP20220079A1 (enExample)
MX (1) MX2022004042A (enExample)
MY (1) MY209387A (enExample)
PE (1) PE20221412A1 (enExample)
PH (1) PH12022550693A1 (enExample)
SA (1) SA522432139B1 (enExample)
TW (1) TWI878355B (enExample)
UA (1) UA130106C2 (enExample)
WO (1) WO2021064137A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
US20240174642A1 (en) 2022-10-26 2024-05-30 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024088991A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
AU2023370123A1 (en) 2022-10-26 2025-04-17 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517844A (ja) 2011-05-21 2014-07-24 マクロジェニクス，インコーポレーテッド ヒト及び非ヒトｃｄ３に結合可能なｃｄ３結合分子
JP2015519337A (ja) 2012-05-07 2015-07-09 トラスティーズ・オブ・ダートマス・カレッジ 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
WO2017181001A1 (en) 2016-04-15 2017-10-19 Trustees Of Dartmouth College High affinity b7-h6 antibodies and antibody fragments
JP2018088938A (ja) 2011-10-10 2018-06-14 ゼンコア インコーポレイテッド 抗体を精製する方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994003678A1 (en) 1992-08-10 1994-02-17 Alcan Aluminium Uk Limited Fence
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1361892A4 (en) 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc BINDING DOMAIN FUSION PROTEIN Immunoglobulin
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
NL1019562C2 (nl) 2001-12-13 2003-06-17 Heineken Tech Services Klepsamenstel voor gebruik bij drankafgifte.
US8764654B2 (en) 2008-03-19 2014-07-01 Zin Technologies, Inc. Data acquisition for modular biometric monitoring system
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
US7858759B2 (en) 2007-10-04 2010-12-28 Zymogenetics, Inc. Anti-zB7H6 antibody-drug conjugates
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
FI20090280L (fi) 2009-07-17 2011-01-18 Kone Corp Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
CN104640561A (zh) * 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3848393A1 (en) 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517844A (ja) 2011-05-21 2014-07-24 マクロジェニクス，インコーポレーテッド ヒト及び非ヒトｃｄ３に結合可能なｃｄ３結合分子
JP2018088938A (ja) 2011-10-10 2018-06-14 ゼンコア インコーポレイテッド 抗体を精製する方法
JP2015519337A (ja) 2012-05-07 2015-07-09 トラスティーズ・オブ・ダートマス・カレッジ 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
WO2017181001A1 (en) 2016-04-15 2017-10-19 Trustees Of Dartmouth College High affinity b7-h6 antibodies and antibody fragments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Human/Cynomolgus Monkey B7-H6 Antibody ，R＆D systems product catalog [online]，2019年05月28日， [検索日 2022.01.04], インターネット: <URL：https://resources.rndsystems.com/pdfs/datasheets/mab10162.pdf>

Also Published As

Publication number Publication date
WO2021064137A2 (en) 2021-04-08
PE20221412A1 (es) 2022-09-20
CN122277744A (zh) 2026-06-26
CN114641496A (zh) 2022-06-17
AR120138A1 (es) 2022-02-02
TW202128756A (zh) 2021-08-01
CA3153372A1 (en) 2021-04-08
JP7809680B2 (ja) 2026-02-02
JOP20220079A1 (ar) 2023-01-30
TWI878355B (zh) 2025-04-01
ECSP22019193A (es) 2022-04-29
CN122080223A (zh) 2026-05-26
US20230340130A1 (en) 2023-10-26
JP2024020414A (ja) 2024-02-14
UA130106C2 (uk) 2025-11-12
US11732045B2 (en) 2023-08-22
MX2022004042A (es) 2022-05-02
BR112022004047A2 (pt) 2022-05-24
SA522432139B1 (ar) 2024-08-29
CO2022003552A2 (es) 2022-04-19
CN114641496B (zh) 2026-01-02
EP4038100A2 (en) 2022-08-10
DOP2022000060A (es) 2022-05-31
JP2022551081A (ja) 2022-12-07
CL2022000664A1 (es) 2023-01-06
US20210107983A1 (en) 2021-04-15
CR20220136A (es) 2022-05-27
KR20220075383A (ko) 2022-06-08
MY209387A (en) 2025-07-07
AU2020358893A1 (en) 2022-03-31
WO2021064137A3 (en) 2021-05-14
PH12022550693A1 (en) 2023-03-27
CN122103354A (zh) 2026-05-29
IL291817A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7809680B2 (ja) 癌処置のための多重特異性結合タンパク質
US12528879B2 (en) Multi-specific binding proteins for cancer treatment
US12275798B2 (en) Tri-specific binding molecules
EA049502B1 (ru) Мультиспецифические связывающие белки для лечения рака
HK40121622A (en) Dll3/cd3 binding proteins for the treatment of cancer
EA047971B1 (ru) Dll3/cd3 связывающие белки для лечения рака
HK40041732B (en) Dll3/cd3 binding proteins for cancer treatment
HK40041732A (en) Dll3/cd3 binding proteins for cancer treatment
WO2024243048A1 (en) Bispecific agonistic antibodies to il12 receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221216

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231115

R150 Certificate of patent or registration of utility model

Ref document number: 7387885

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150